Idelalisib-rituximab induces durable remissions in TP53 disrupted B-PLL but results in significant toxicity: updated results of the UK-wide compassionate use programme.

Br J Haematol

Department of Haematology, Oxford University Hospitals NHS Trust, Churchill Hospital, Oxford, UK.

Published: February 2019

Download full-text PDF	Source
http://dx.doi.org/10.1111/bjh.15151	DOI Listing

Publication Analysis

idelalisib-rituximab induces

induces durable

durable remissions

remissions tp53

tp53 disrupted

disrupted b-pll

b-pll toxicity

toxicity updated

updated uk-wide

uk-wide compassionate

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!